Purpose: On March 4, 2022, the US Food and Drug Administration (FDA) approved nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer (NSCLC). We discuss the FDA's review of the key data and regulatory considerations supporting this approval.

Patients And Methods: The approval was based on the results of CheckMate 816, an international, multiregional, active-controlled trial that randomly assigned 358 patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (N2) per the American Joint Committee on Cancer seventh staging edition to receive either nivolumab plus platinum-doublet or platinum-doublet chemotherapy alone for three cycles before planned surgical resection. The major efficacy end point that supported this approval was event-free survival (EFS).

Results: At the first planned interim analysis (IA), the hazard ratio (HR) for EFS was 0.63 (95% CI, 0.45 to 0.87; = .0052; statistical significance boundary = .0262) favoring the nivolumab plus chemotherapy arm; the median EFS was 31.6 months (95% CI, 30.2 to not reached) in the nivolumab plus chemotherapy arm versus 20.8 months (95% CI, 14.0 to 26.7) in the chemotherapy-only arm. At the time of a prespecified IA for overall survival (OS), 26% of patients had died, and the HR for OS was 0.57 (95% CI, 0.38 to 0.87; = .0079; statistical significance boundary = .0033). Eighty-three percent of patients in the nivolumab-containing arm versus 75% in the chemotherapy-only arm received definitive surgery.

Conclusion: This approval, the first for any regimen for the neoadjuvant treatment of NSCLC in the United States, was supported by a statistically significant and clinically meaningful improvement in EFS with no evidence of detriment in OS or negative impact on patients' receipt and timing of surgery or surgical outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256356PMC
http://dx.doi.org/10.1200/JCO.22.02509DOI Listing

Publication Analysis

Top Keywords

nivolumab platinum-doublet
12
platinum-doublet chemotherapy
12
neoadjuvant treatment
12
patients resectable
12
food drug
8
drug administration
8
chemotherapy neoadjuvant
8
treatment patients
8
resectable non-small-cell
8
non-small-cell lung
8

Similar Publications

The standard first-line treatment for unresectable advanced or recurrent gastric cancer(GC)and gastroesophageal junction cancer(GEJC)has been a platinum doublet chemotherapy. Trastuzumab with chemotherapy is the standard regimen for HER2-positive GC/GEJC. While, for HER2-negative cases, chemotherapy with or without immune checkpoint inhibitors (ICIs)such as nivolumab or pembrolizumab are regarded as the standard therapy.

View Article and Find Full Text PDF

Objectives: This study assessed the cost-effectiveness of nivolumab plus ipilimumab (NIVO+IPI) versus platinum-doublet chemotherapy (chemo) in untreated metastatic non-small cell lung cancer (NSCLC) using mixture-cure modelling, an approach used to analyse immuno-oncology treatments due to their underlying methods depicting delayed but durable response in some patients.

Methods: A mixture-cure economic model was developed from a US third-party payer perspective to assess the lifetime costs and benefits of NIVO+IPI versus chemo using data from Part 1 of the phase III CheckMate 227 trial with 5 years of follow-up. The model consisted of four health states: progression-free without long-term response (non-LTR), progression-free with long-term response (LTR), post-progression, and death.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of combined treatment with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) antibodies compared to standard platinum-based chemotherapy in older patients with advanced non-small-cell lung cancer (NSCLC).
  • It focuses specifically on patients aged 70 years or older or those with an ECOG performance status of 2, as there is limited data on this demographic.
  • The trial is a phase 3 randomized controlled study conducted across 30 sites in France, aiming to evaluate overall survival, progression-free survival, and safety of the treatments in the intended patient population.
View Article and Find Full Text PDF

Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).

Eur J Cancer

November 2024

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address:

Article Synopsis
  • The study investigates the impact of dual immunotherapy (nivolumab and ipilimumab) along with platinum-based chemotherapy on patients with untreated brain metastases from non-small cell lung cancer (NSCLC).
  • In total, 30 patients were enrolled, and the results showed a 50% intracranial response rate with a 20% rate of complete response, indicating effectiveness in targeting brain lesions.
  • The findings suggest that this treatment combination has promising potential for managing NSCLC patients with brain metastases, achieving a median intracranial progression-free survival of 8.1 months.
View Article and Find Full Text PDF

Background: In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC.

Methods: This single-arm, phase-II trial enrolled operable T3-4N0-2 patients with NSCLC without oncogenic drivers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!